A Phase 2 Trial of Five-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma.

CONCLUSIONS: A shorter five-day neoadjuvant RT regimen results in favorable rates of wound complications and grade ≥2 toxicity after two years follow-up. Five-day RT significantly increased utilization of neoadjuvant RT at our high-volume sarcoma center. With further validation, a putative germline biomarker for wound complications may guide safer RT utilization.
PMID: 32054730 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 12, 2020 Category: Cancer & Oncology Authors: Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry S, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal N, Steinberg ML, Weidhaas JB, Eilber FC Tags: Clin Cancer Res Source Type: research